31 May 2024 in Blood Advances
No US Food and Drug Administration- or European Medicines Agency-approved therapies exist for bleeding due to hereditary hemorrhagic telangiectasia (HHT), the second-most common inherited bleeding disorder worldwide. The current standard of care (SOC) includes iron and red cell supplementation, alongside the necessary hemostatic procedures, none of which target underlying disease pathogenesis. Recent evidence has demonstrated that bleeding pathophysiology is amenable to systemic antiangiogenic therapy with the anti-vascular endothelial growth factor bevacizumab. Despite its high cost, the addition of longitudinal bevacizumab to the current SOC may reduce overall health care resource use and improve patient quality of life. We conducted, to our knowledge, the first cost-effectiveness analysis of IV bevacizumab in patients with HHT with the moderate-to-severe phenotype, comparing bevacizumab added to SOC vs SOC alone. The primary outcome was the incremental net monetary benefit (iNMB) reported over a lifetime time horizon and across accepted willingness-to-pay thresholds, in US dollar per quality-adjusted life year (QALY). Bevacizumab therapy accrued 9.3 QALYs while generating $428 000 in costs, compared with 8.3 QALYs and $699 000 in costs accrued in the SOC strategy. The iNMB of bevacizumab therapy vs the SOC was $433 000. No parameter variation and no scenario analysis, including choice of iron supplementation product, changed the outcome of bevacizumab being a cost-saving strategy. Bevacizumab therapy also saved patients an average of 133 hours spent receiving HHT-specific care per year of life. In probabilistic sensitivity analysis, bevacizumab was favored in 100% of all 10 000 Monte Carlo iterations across base-case and all scenario analyses. Bevacizumab should be considered for more favorable formulary placement in the care of patients with moderate-to-severe HHT.
25 February 2026 in Blood Advances
Iron-deficiency anemia (IDA) affects nearly one-third of women globally, with heavy menstrual bleeding (HMB) being a significant risk factor among those of reproductive age. Despite the substantial burden of HMB-related IDA, patients often face delays in receiving effective treatment. Oral iron is typically used as first-line therapy, despite frequent gastrointestinal side effects and challenges in treatment adherence. This study evaluated the reproductive life span cost-effectiveness of first-line intravenous (IV) vs oral iron therapy for women with HMB and IDA. We developed a Markov model simulating a cohort of women aged 18 to 51 years, comparing first-line treatment with IV iron dextran, IV ferumoxytol, IV iron sucrose, or oral ferrous sulfate. Costs and quality-adjusted life years (QALYs) were estimated from the societal perspective. IV iron dextran was the cost-effective treatment, yielding 19.26 QALYs at a cost of $157 500, compared with 19.10 QALYs at $152 900 for oral ferrous sulfate. The incremental cost-effectiveness ratio for IV iron dextran was $28 600 per QALY. Treatment with IV ferumoxytol and iron sucrose cost $158 300 and $163 500, respectively, and did not provide additional QALY benefit compared with IV iron dextran, which remained the cost-effective treatment across a range of scenarios and sensitivity analyses. Our findings indicate that first-line treatment with IV iron dextran is the cost-effective strategy for managing IDA in women with HMB at commonly accepted willingness-to-pay thresholds. These results support expanding access to IV iron as a first-line option, and highlight the need to reduce treatment delays and insurance-related barriers.
29 April 2024 in Journal of Vascular and Interventional Radiology
13 May 2026 in Blood Advances
Maternal iron deficiency (ID) affects nearly 85% of all pregnancies worldwide by the third trimester and is significantly linked with maternal morbidity, poor birth outcomes, and cognitive and behavioral developmental deficits in children. Despite its burden to maternofetal health, no guidelines exist for the regular screening of ID in pregnant individuals in the United States. The World Health Organization (WHO) employs a diagnostic (i.e., non-screening) ferritin threshold of 15µg/L for ID in the first trimester of pregnancy, with no guidance in the second and third trimesters. Regular ID screening in pregnancy will capture the large proportion of mothers who remain undiagnosed and untreated under the current clinical status quo. Accordingly, we conducted the first cost-effectiveness analysis of ferritin-based ID screening in pregnant women in the United States, comparing thresholds of 1) 30µg/L versus 2) 15µg/L versus 3) no screening from a modified US societal perspective - accounting for wages lost to infusion time, infusion administration costs, and cost of annual hematology follow up. We found that screening at 30µg/L is the preferred strategy across extensive base case, threshold, and sensitivity analyses and across all examined willingness-to-pay (WTP) thresholds, with an incremental cost-effectiveness ratio (ICER) of $34,000/quality-adjusted life-year (QALY) [95% credible interval $32,000 - $36,200/QALY] compared with no screening. No parameter variation changed this outcome, and screening at 30µg/L was favored in 100% of 10,000 Monte Carlo iterations. Population-level regular second and third trimester screening for ID using physiologically-informed ferritin ranges should be considered for all pregnant women in the United States.